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Abstract
Background: TGF-b1 is involved in cardiac remodeling through an auto/paracrine mechanism. The contribution of TGF-b1
from plasmatic source to pressure overload myocardial remodeling has not been analyzed. We investigated, in patients with
valvular aortic stenosis (AS), and in mice subjected to transverse aortic arch constriction (TAC), whether plasma TGF-b1
relates with myocardial remodeling, reflected by LV transcriptional adaptations of genes linked to myocardial hypertrophy
and fibrosis, and by heart morphology and function.
Methodology/Principal Findings: The subjects of the study were: 39 patients operated of AS; 27 healthy volunteers; 12
mice subjected to TAC; and 6 mice sham-operated. Myocardial samples were subjected to quantitative PCR. Plasma TGF-b1
was determined by ELISA. Under pressure overload, TGF-b1 plasma levels were significantly increased both in AS patients
and TAC mice. In AS patients, plasma TGF-b1 correlated directly with aortic transvalvular gradients and LV mass surrogate
variables, both preoperatively and 1 year after surgery. Plasma TGF-b1 correlated positively with the myocardial expression
of genes encoding extracellular matrix (collagens I and III, fibronectin) and sarcomeric (myosin light chain-2, b-myosin heavy
chain) remodelling targets of TGF-b1, in TAC mice and in AS patients.
Conclusions/Significance: A circulating TGF-b1-mediated mechanism is involved, in both mice and humans, in the
excessive deposition of ECM elements and hypertrophic growth of cardiomyocytes under pressure overload. The possible
value of plasma TGF-b1 as a marker reflecting preoperative myocardial remodeling status in AS patients deserves further
analysis in larger patient cohorts.
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Introduction
Aortic valve stenosis (AS) is one of the most common valvular
diseases whose prevalence is likely to rise in the future with the
increase in life expectancy of the population [1]. This entity
promotes a pure, progressive, LV pressure overload, which is
responsible for biomechanical stress, alterations in the humoral cell
environment, and activation of numerous signaling pathways,
bringing about structural and functional changes in the myocar-
dium. Typically, LV remodeling under pressure overload is
characterized by hypertrophic growth of cardiomyocytes, prolif-
eration of cardiac fibroblasts, increased deposition of extracellular
matrix (ECM) constituents and loss of myocytes with fibrotic
replacement [2]. The major long-term consequences of this
remodeling process are increased myocardial stiffness and
decreased compliance resulting, initially, in diastolic dysfunction
and, over time, in combined diastolic and systolic heart failure.
Abundant experimental evidence indicates that Transforming
Growth Factor-b1 (TGF-b1) is critically involved in major
structural changes of the myocardium under pressure overload
[3,4]. TGF-b1 acts on cardiomyocytes as well as on cardiac
fibroblasts inducing hypertrophy of the former, synthesis of ECM
materials by the latter [4] and endothelial-to-mesenchymal
transition that recruits fibroblasts to the myocardium [5]. In
addition, TGF-b1 is critically involved in phenotypic modulation
of fibroblasts into matrix-producing myofibroblasts [6].
Few studies have dealt with such a role for TGF-b1 in human
hypertrophied myocardium from pressure-overload related heart
pathologies [7], including AS [8,9]. Other groups and ours have
previously reported increased myocardial expression (at the
mRNA and/or protein levels) of TGF-b1 in patients with severe
AS, together with upregulation of collagens I and III and
fibronectin, as well as the sarcomeric protein myosin light chain-
2 [8,9]. Our results also support a regulatory role for myocardial
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genes, mediated by both the SMAD and the TGF-b activated
kinase 1 (TAK1) signaling pathways [9].
The available experimental reports are focused in analyzing the
autocrine and/or paracrine effects of TGF-b1 released by
cardiomyocytes [10] and fibroblasts [11]. In the present study,
we investigated, in mice subjected to aortic arch constriction and
in patients with severe valvular AS, the contribution of TGF-b1
from circulating source to pressure overload-induced myocardial
remodeling, as reflected by LV transcriptional changes of genes
linked to myocardial hypertrophy and fibrosis, and by changes in
echocardiographic heart morphology and function.
Results
Demographics and Clinical Characteristics of Patients
The characteristics of the cohorts are shown in Table 1. There
were no significant differences between control and AS groups in
mean age and incidence of atrial fibrillation-flutter. Concerning
LV hypertrophy related factors, the mean body mass index and
the incidence of obesity and diabetes did not differ between AS
men and women and their control pairs. A history of systemic
hypertension and the use of diuretics were more frequent among
AS women than their controls, but the average systolic and
diastolic blood pressures were higher in the control group. There
were no other significant differences in the pharmacologic
treatment with ACE inhibitors, angiotensin-II receptor antago-
nists, diuretics (in men), calcium antagonists, statins or b-blockers
between the groups.
Echocardiographic Data
Men and women with AS exhibited no significant difference in
aortic valve gradients, or in mean aortic valve area index to body
surface area (Table 1), although men displayed a larger crude
aortic valve area (0.6660.03 vs 0.5560.02 cm
2, p,0.01). AS
patients of both genders, compared to controls, showed signifi-
cantly greater indexed IVST and PWT, and lower LVEDr/PWT
ratio. No significant difference in LVEF was found between
groups. The AS cohorts showed a significant increase in LVMI,
compared with controls (Fig. 1A). One year after surgery, LVMI is
normalized but PWTI reduction, albeit significant, did not reach
the values of healthy controls (Fig. 1B).
AS Patients Show Increased Plasma Levels of TGF-b1i n
Comparison with Healthy Controls
As shown in Figure 2A, AS patients show significantly higher
preoperative plasma levels of TGF-b1 when compared with
Table 1. Characteristics of patients.
Control Aortic Stenosis
Men(n=14) Women(n=13) Men(n=21) Women(n=18)
Age (yrs6SEM) 71.961.6 69.162.2 70.363.0 72.662.6
Systemic hypertension, n (%) 3 (21) 1 (8) 11 (52) 9 (50) *
Body Mass Index, kg/m
2 27.660.7 26.861.1 28.061.0 29.261.4
Body Mass Index $30, n (%) 2 (14) 3 (23) 5 (24) 7 (39)
Diabetes Mellitus 0 0 6 (29) 2 (11)
ACE inhibitors, n (%) 2 (14) 3 (25) 6 (29) 2 (11)
AT-II receptor antagonists, n (%) 1(7) 1 (8) 1 (5) 2 (11)
Diuretics, n (%) 2 (14) 2 (17) 5 (24) 10 (56) *
Calcium antagonists, n (%) 1 (7) 1 (8) 0 4 (22)
b-Blockers, n (%) 1 (7) 2 (17) 2 (10) 2 (11)
Statins, n (%) 5 (36) 1 (8) 2 (10) 5 (28)
Atrial fibrillation or flutter, n (%) 1 (7) 0 3 (14) 4 (22)
Systolic blood pressure, mm Hg 121.369.7 142.666.3 118.164.7 120.464.5 *
Diastolic blood pressure, mm Hg 69.265.2 82.662.0 64.962.4 66.163.4 *
Peak AV gradient, mm Hg –– 1 0 3 671 1 0 65
Mean AV gradient, mm Hg –– 6 3 646 5 63
Aortic valve area index, cm
2/m
2 – – 0.3660.02 0.3360.01
LVEDDI, mm/m 30.961.0 29.860.8 32.260.7 30.560.8
IVSTI, mm/m 7.060.3 6.560.4 9.360.4 *** 9.060.5 **
PWTI, mm/m 6.060.3 5.760.3 7.860.2 *** 8.160.4 ***
LV ejection fraction, % 61626 3 636 1 636 1 63
LVEDr/PWT 2.760.2 2.760.1 2.160.1 ** 2.060.1 ***
LVMI, g/m
2.7 53.763.6 46.564.0 84.364.3 *** 76.265.5 ***
LVEDDI: Left ventricular end-diastolic diameter index to height; IVSTI: Interventricular septum thickness index to height; PWTI: Posterior wall thickness index to height;
LVEDr/PWT: Left ventricular end-diastolic radius to posterior wall thickness ratio; LVMI: Left ventricular mass index to height
2.7
*p,0.05;
**p,0.01;
***p,0.001 (two tailed unpaired t test versus same gender control patients).
doi:10.1371/journal.pone.0008476.t001
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PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8476Figure 1. Evolution of left ventricucular mass and posterior wall thickness after aortic valve replacement. Left ventricular mass (in
grams) indexed to the height (in meters) of the patient
2.7 (LVMI) (A) and posterior wall thickness (in mm) indexed to the height (in meters) (B)i n
control volunteers, and in AS patients preoperatively and one year after valvular replacement. Results are expressed as mean6SEM. *** p,0.001 and
** p,0.01 vs healthy controls; ### p,0.001 vs preoperative values (one-way ANOVA and Bonferroni’s post-hoc test).
doi:10.1371/journal.pone.0008476.g001
Figure 2. Pre- and one year postoperative plasma levels of TGF-b1 and their relationships with echocardiographic parameters. A:
Plasma TGF-b1 levels in control volunteers, and in AS patients preoperatively and one year after valvular replacement. Results are expressed as
mean6SEM. *p,0.05 and ***p,0.001 vs control volunteers (one-way ANOVA followed by Bonferroni’s test). B: Regression lines showing, in AS
patients, the correlation between plasma TGF-b1 concentrations and the mean transvalvular gradients preoperatively (N) and, one year after aortic
valve replacement (#), with the residual mean transprosthetic gradients. (Pearson’s regression analysis). C and D: Regression lines showing, in AS
patients, the correlation between plasma TGF-b1 concentrations and posterior wall indexed to the height (PWTI) preoperatively (C) and one year after
aortic valve replacement (D). (Pearson’s regression analysis).
doi:10.1371/journal.pone.0008476.g002
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24.262.2 ng/ml). Plasma levels of TGF-b1 determined in
peripheral venous blood did not differ significantly from levels
measured in the coronary sinus (19.763.4 ng/ml). One year after
surgery, TGF-b1 plasma levels experiment a significant reduction
when compared with preoperative values (AS patients, 1 year after
surgery: 18.461.3 ng/ml), but do not reach the values of healthy
controls (Fig. 2A).
Plasma Levels of TGF-b1 Are Positively Correlated to
Mean Gradients and with Hypertrophy-Related
Echocardiographic Parameters in AS Patients
A significant and positive correlation between peripheral TGF-
b1 plasma levels and mean aortic transvalvular gradients (Fig. 2B)
was evident in AS patients. Four months (data not shown) and one
year after surgery, plasma TGF-b1 levels still maintain the positive
correlation with the residual mean transprosthetic gradients
(Fig. 2B).
Plasma TGF-b1 levels, both preoperatively and 1 year after
surgery (Figs. 2C and D), display a significant and direct
correlation with PWTI in all AS patients. In addition, a
relationship between preoperative TGF-b1and LVMI (r=0.72,
p,0.01) and IVSI (r=0.67, p,0.01) was evident only in AS
women.
TGF-b1 Plasma Levels Are Positively Correlated with LV
Myocardial Expression Levels of Genes Encoding
Effectors of the TGF-b1 Signalling Pathways, and with
TGF-b1 Target Genes, Encoding Remodelling-Related
Proteins
Preoperative plasma levels of TGF-b1 in AS patients sustain a
significant positive correlation with LV myocardial SMAD-2 and
TAK-1 transcript levels (Fig. 3). The myocardial expression of
genes regulated by TGF-b1, such as the ECM elements collagen I,
collagen III and fibronectin (Fig. 4) and the sarcomeric proteins
myosin light chain-2 and b-myosin heavy chain (Fig. 5), are also
directly correlated with plasma TGF-b1 concentrations.
To ascertain whether the myocardium was the main source of
plasma TGF-b1 in AS patients, the relationship between plasma
and myocardial transcript levels of the cytokine was tested. No
significant correlation between both parameters was evidenced
(r=0.27; p=0.1).
Mice Subjected to Pressure Overload Feature the Same
Response to Plasmatic TGF-b1 than AS Patients
As shown in figure 6, plasma levels of TGF-b1 are significantly
higher in TAC mice than in sham controls (sham: 0.3660.05 vs
TAC: 2.4460.43; p,0.05), and maintain a significant and positive
correlation with myocardial mRNA levels of collagens I and III,
fibronectin, b-myosin heavy chain, and with a-myosin heavy
chain, which is the predominant isoform in rodents. A positive
correlation between plasma TGF-b1 and heart weight index at
sacrifice (normalized to body mass) was also evidenced (r=0.56;
p,0.05).
Discussion
In the present study, we show that preoperative peripheral
venous TGF-b1 plasma levels appear increased in AS patients
compared with age-matched healthy individuals. Few days after
surgery, some AS patients show a transient increase in TGF-b1
levels (data not shown), probably in relation with surgical wound
healing processes. During postdischarge follow-up, plasma TGF-
b1 recedes significantly, although on the average values do not
normalize during the subsequent 12 months. This finding agrees
with the well documented notion that reverse LV remodeling after
aortic valve replacement in AS patients starts immediately after
operation [12], but progresses at a slow pace taking several years
to be completed, if ever [13].
A remarkable observation is that, before surgery, plasma levels
of TGF-b1 were proportional to the degree of pressure overload
the LV of AS patients had to bear, suggesting a link between the
severity of the pathology and the release of TGF-b1 to the plasma.
Furthermore, 4 months (data not shown) and 1 year after aortic
valve replacement, TGF-b1 plasma levels still maintain a
significant positive correlation with the residual transprosthetic
gradients, so that these two variables still follow a parallel evolution
after removing the hemodynamic burden. As to echocardiograph-
ic hypertrophy parameters is concerned, we observed that
preoperative PWTI kept a close relationship with plasma TGF-
b1 in all AS patients, and with LVMI and IVSTI in AS women.
Figure 3. Relationships between circulating TGF-b1a n d
myocardial gene expression of its canonical and non-canonical
effectors. Regression lines show the positive correlation between TGF-
b1 plasma levels and LV myocardial mRNA expression of SMAD-2 (A)
and TAK-1 (B) in AS patients. The relative mRNA expression was
normalized vs the housekeeping gene, ribosomal subunit 18S, and
multiplied by 10
5. (Pearson’s regression analysis).
doi:10.1371/journal.pone.0008476.g003
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PWTI for the complete cohort. These results would indicate that
there is an association of TGF-b1 blood concentration with
functional and anatomical parameters reflecting the myocardial
changes under pressure overload, so that its levels vary in parallel
with changes in the above parameters after valvular replacement.
The key role for myocardial TGF-b1 in the regulation of
cardiomyocyte hypertrophic growth and ECM deposition during
remodeling following pressure overload is well documented in the
experimental animal [3,4] and in a few reports in human related
pathologies [8,9]. The available experimental data reinforce the
view that TGF-b1, released by cardiomyocytes [10] and fibroblasts
[11], exerts its effects by acting in an autocrine and/or paracrine
manner. In the human scenario, circumstantial evidence sugges-
tive for a contribution of TGF-b1 from a plasmatic source to
pressure overload myocardial remodeling was provided by some
reports showing that TGF-b1 plasma levels are increased in
hypertensive patients, with or without metabolic syndrome [14]
with target organ damage, including heart hypertrophy [15,16].
However, the absence in these studies of data from myocardial
biopsies precludes the establishment of a cause-effect relationship
between plasma TGF-b1 and LV remodeling. Matt and colleagues
[17] reported recently that, in an experimental mutant mouse
model of Marfan syndrome that recapitulates the cardiovascular
involvement of the disease, circulating levels of TGF-b1 were
significantly increased and correlated with the aortic root
diameter. They also suggested the potential value of plasma level
of this cytokine in Marfan patients, as a marker of disease
progression and/or therapeutic response to treatments [17]. Here,
the myocardial transcriptional changes, hallmarks of AS, seem to
be under the influence of circulating TGF-b1, as suggested by the
direct correlation between preoperative plasma levels of TGF-b1
and LV expression of genes encoding ECM elements (collagens I
and III and fibronectin) as well as sarcomeric elements (b-myosin
heavy chain and myosin light chain-2). Further, these relationships
were absent in the myocardium from a cohort of 16 patients
operated of cardiac pathologies, with no LV pressure or volume
overload (data not shown).
Inferences from the clinical study are limited by the inherent
heterogeneity of patients that exhibit many conditions known to
have an influence on LV remodeling (systemic hypertension,
obesity, diabetes, medical treatments, lack of genetic homology,
unknown duration of the pressure overload situation, etc) and
could contribute to weaker, albeit significant, linearity of the
correlations. To incorporate further evidence, and using a reverse
translational approach, we also showed that this blood borne
mediated mechanism is operative in mice subjected to TAC, as
plasma TGF-b1 and myocardial gene expression of remodeling
elements are linked by a relationship similar to the one found in
human patients. Important inferences from these results are that,
in LV pressure overload, circulating TGF-b1 contributes to the
progression of myocardial hypertrophy and fibrosis and, in
patients with valvular aortic stenosis, mirrors the myocardial
transcriptional activity.
The direct correlation between plasma levels of TGF-b1 and
myocardial expression of genes encoding SMAD-2 and TAK-1
reinforces the hypothesis that LV remodeling is dependent not
only on local, but also on circulating TGF-b1 mediated
mechanisms, involving both canonical and non-canonical down-
stream effectors, and suggests that the intracellular effectors of
TGF-b1 signaling are under the transcriptional influence of
circulating TGF-b1.
Our experimental approach does not allow ascertaining the full
spectrum of plasmatic TGF-b1 sources, which can be numerous
Figure 4. Relationships between circulating TGF-b1a n d
myocardial gene expression of its target genes of ECM
remodeling. Regression lines show the positive correlation between
preoperative plasma levels of TGF-b1 and myocardial mRNA expression
levels of A: collagen I (COLIa1), B: collagen III (COLIIIa1) and C:
fibronectin in AS patients. The relative mRNA expression was
normalized vs the housekeeping gene, ribosomal subunit 18S, and
multiplied by 10
5. (Pearson’s regression analysis).
doi:10.1371/journal.pone.0008476.g004
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PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8476Figure 5. Relationships between circulating TGF-b1 and myocardial gene expression of sarcomeric target genes. Regression lines
show the positive significant correlation between preoperative plasma levels of TGF-b1 and myocardial mRNA expression levels of b-myosin heavy
chain (A) and myosin light chain-2 (B), in AS patients. The relative mRNA expression was normalized vs the housekeeping gene, ribosomal subunit
18S, and multiplied by 10
5. (Pearson’s regression analysis).
doi:10.1371/journal.pone.0008476.g005
Figure 6. Circulating TGF-b1 in pressure overloaded mice and its relationships with mRNA expression of ECM and sarcomeric
remodeling proteins. A: Plasma TGF-b1 levels in sham (n=6) and pressure overloaded mice (n=12). Results are means6SEM. **p,0.01 vs sham
controls (Student’s t test). Bt oF : Regression lines showing, in 1, and 4 wk TAC mice, the correlation between plasma TGF-b1 concentrations and
myocardial mRNA expression levels of B: Collagen I (COLIa1), C: Collagen III (COLIIIa1), D: Fibronectin, E: a-myosin heavy chain and F: b-myosin heavy
chain. The relative mRNA expression was normalized vs the housekeeping gene, ribosomal subunit 18S, and multiplied by 10
5. (Pearson’s regression
analysis).
doi:10.1371/journal.pone.0008476.g006
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myocardium. However, in our cohort of patients, the absence of a
significant relationship between TGF-b1 mRNA expression in LV
myocardial and its concentration in neither peripheral nor
coronary sinus blood (data not shown) precludes a major
contribution of myocardial tissue to circulating TGF-b1 in this
pathology. In addition, coronary sinus and peripheral venous
blood concentrations of TGF-b1 were similar, even though the
coronary sinus blood has been reported to reflect better the
myocardial status of some remodeling-related biomarkers [19,20].
Should the myocardium be the main source of plasma TGF-b1,
then a positive gradient from its concentration in coronary sinus
blood towards peripheral vein blood would have been evident.
Furthermore, in TAC mice, myocardial and plasmatic TGF-b1
did not correlate either (data not shown). Thus, our data suggest
that other sources apart from the myocardium may have
additionally contributed to an excess plasma TGF-b1 in response
to pressure overload. Putative contributors could be, among
others, the stressed endocardium [21], the circulating blood cells
activated by shear stress in the restricted aortic orifice region [22]
or, in AS patients, the sclerosed aortic valve tissue [23].
In summary, the present study provides new evidence on the
involvement of a circulating TGF-b1-mediated mechanism in the
excessive deposition of ECM elements and hypertrophic growth of
cardiomyocytes in response to pressure overload. Given the
moderate power of the association between circulating TGF-b
andLV remodeling variables,a single elevated value ofthis cytokine
in patients with aortic stenosis would be of limited help in surgical
decision taking. However and according to our results, an escalating
time course of the circulating cytokine may reflect progressive
myocardial hypertrophy and fibrosis and could be an additional
argument for surgery in some asymptomatic or poorly symptomatic
patients. Further clinical longitudinal studies arewarrantedinlarger
patientpopulations toconfirm the relative meritofcirculatingTGF-
b as a clinically useful biomarker of LV remodeling.
Materials and Methods
Ethics Statement
The study followed the Declaration of Helsinki guidelines for
investigation on human subjects. The University Hospital
Valdecilla Institutional Ethics and Clinical Research Committee
approved the study, and all patients gave written informed
consent.
The use of mice in the study was approved by the University of
Cantabria Institutional Laboratory Animal Care and Use
Committee and carried out in accordance with the Declaration
of Helsinki and the European Communities Council Directive
(86/609/EEC).
Patients
The study was performed on myocardial and plasma samples
obtained prospectively from 39 patients with severe AS undergoing
cardiac surgery (21 men and 18 women). Patients with aortic or
mitral regurgitation greater than mild and patients with major
coronary stenosis greater than 50% were ineligible for the study.
The control group was constituted by 27 healthy volunteers that
were recruited for their ages similar to those of AS patients and lack
of previous cardiac disease. The clinical and echocardiographic
characteristics of both AS and control groups are shown in Table 1.
Echocardiography
A two-dimensionally guided M-mode transthoracic echocardio-
gram was performed (Philips-Hewlett Packard, IE 33) in AS
patients preoperatively, prior to hospital discharge after valve
replacement, and four months and one year postoperatively. In the
control individuals, a similar study was performed at the time of
blood sampling.
M-mode tracings were digitally recorded and analyzed. Internal
LVEDD and LVESD diameters, IVST, and PWT were recorded.
LV dimensions and wall thicknesses were indexed to the height of
the patient. Relative LV end diastolic radius was expressed as the
ratio between LV cavity end-diastolic radius and PWT. LVEF was
calculated using Quin ˜ones formula, and LVM according to
Devereux formula [24], indexed to height of the patient to the
2.7
th power [25] and expressed in g/m
2.7.
Blood Sampling and Determination of TGF-b1 Plasma
Levels
Samples were collected from peripheral venous blood of healthy
volunteers and AS patients. In the latter group, samples were
drawn 24 h preoperatively, at operation from the coronary sinus
and, in the postoperative period, at the time of the echocardio-
graphic studies. To minimize platelet degranulation [18], blood
was drawn from an antecubital vein without tourniquet, using a
syringe with a wide-gauge needle and then gently transferred to a
collection tube containing EDTA. Within 15 minutes of blood
collection, plasma was separated by centrifugation at 10006g for
30 minutes. Plasma aliquots were stored at 280uC until analysis.
Total TGF-b1 plasma levels were determined by ELISA (Biotrak
Easy ELISA, GE Healthcare), following the manufacturer’s
instructions.
Myocardial Sampling and Quantitative PCR
During surgery, myocardial tru-cut needle biopsies (4–10 mg)
were taken from the lateral LV wall and immediately frozen in
liquid nitrogen.
Total myocardial RNA was retro-transcribed into cDNA.
Quantitative PCR was conducted using specific TaqMan assays
(Applied Biosystems). The expression of genes encoding TGF-b1,
collagen I, collagen III, fibronectin, myosin light chain-2 and b-
myosin heavy chain was normalized to the housekeeping gene,
ribosomal subunit 18S, measured in parallel in each sample.
Duplicate transcript levels were determined in three independent
experiments. Results are expressed as 2
(housekeeping Ct-problem Ct)
multiplied by 10
5, being Ct the cycle threshold.
Pressure Overload Studies in Mice
The experiments were performed in adult (16–20 weeks old)
C57BL/6 mice, housed in a room kept at 22uC with 12:12 h
light/dark cycle, and provided with food and water ad libitum.
Pressure overload was induced by controlled constriction of the
transverse aortic arch (TAC) as described previously [26]. Briefly,
mice were anesthetized by intraperitoneal injection of ketamine
(10 mg/kg) and xylazine (15 mg/kg). The aorta was constricted at
the mid arch level with a 7/0 polypropylene ligature using as
calibrator a blunted 27-gauge (0.41 mm OD) needle, reaching
approximately a 70% stenosis in diameter. Mice were sham
operated (n=6) or subjected to TAC for 1 or 4 weeks (n=6 per
group). After completing their follow-up, mice were anesthetized
with ketamine and xylazine, blood samples were collected from the
retroorbitary sinus, and LV samples were immediately frozen in
liquid nitrogen for RNA extraction. Plasma levels of TGF-b1 were
determined by ELISA, and myocardial expression of genes
encoding TGF-b1, collagen I, collagen III, fibronectin, a-myosin
heavy chain and b-myosin heavy chain by real time PCR, as
described below for patients.
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GraphPad Prism 5.01 software package was used. Values are
reported as means6S.E.M. Student’s t-test was used to assess
differences between means of continuous variables. Multiple
comparisons were performed using the one-way ANOVA followed
by Bonferroni’s test. Categorical data were compared by Fisher’s
exact test. Pearson’s regression analysis was used to detect
correlations between plasma and gene expression levels and/or
echocardiographic parameters. A p value,0.05 was considered
significant.
Acknowledgments
We acknowledge the technical assistance of Milagros Chasco, R.N., Alaska
Ferna ´ndez, R.N., Rosario Garralda, R.N., Raquel de la Pinta, Nieves
Garcı ´a, Ana Sandoval and Amalia Cavaye ´.
Author Contributions
Conceived and designed the experiments: AVV MAH JFN. Performed the
experiments: AVV MC ML CM FGV RMD JFN. Analyzed the data:
AVV MC ML CM MAH JFN. Contributed reagents/materials/analysis
tools: FGV RMD MAH. Wrote the paper: AVV MAH JFN.
References
1. Lindroos M, Kupari M, Heikkila J, Tilvis R (1993) Prevalence of aortic valve
abnormalities in the elderly: an echocardiographic study of a random population
sample. J Am Coll Cardiol 21: 1220–1225.
2. Hill JA, Olson EN (2008) Cardiac Plasticity. N Engl J Med 358: 1370–1380.
3. Bujak M, Frangogiannis NG (2007) The role of TGF-b signaling in myocardial
infarction and cardiac remodeling. Cardiovascular Research 74: 184–195.
4. Azhar M, Schultz Jel J, Grupp I, Dorn GW 2nd, Meneton P, et al. (2003)
Cytokine Transforming growth factor beta in cardiovascular development and
function. Growth Factor Rev 14: 391–407.
5. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, et al.
(2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat
Med 13: 952–961.
6. Petrov VV, Fagard RH, Lijnen PJ (2002) Stimulation of collagen production by
transforming growth factor-beta1 during differentiation of cardiac fibroblasts to
myofibroblasts. Hypertension 39: 258–263.
7. Villarreal FJ, Dillmann WH (1992) Cardiac hypertrophy-induced changes in
mRNA levels for TGF-beta 1, fibronectin, and collagen. Am J Physiol 262:
H1861–1866.
8. Fielitz J, Hein S, Mitrovic V, Pregla R, Zurbru ¨gg HR, et al. (2001) Activation of
the cardiac renin-angiotensin system and increased myocardial collagen
expression in human aortic valve disease. J Am Coll Cardiol 37: 1443–1449.
9. Villar AV, Llano M, Cobo M, Expo ´sito V, Merino R, et al. (2009) Gender
differences of echocardiographic and gene expression patterns in human
pressure overload left ventricular hypertrophy. J Mol Cell Cardiol 46: 526–535.
10. Takahashi N, Calderone A, Izzo NJ Jr, Ma ¨ki TM, Marsh JD, et al. (1994)
Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat
ventricular myocytes. J Clin Invest 94: 1470–1476.
11. Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS (1998) Angiotensin II
stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and
endothelin-1 from fibroblasts. Cardiovasc Res 40: 352–363.
12. Christakis GT, Joyner CD, Morgan CD, Fremes SE, Buth KJ, et al. (1996) Left
ventricular mass regression early after aortic valve replacement. Ann Thorac
Surg 62: 1084–1089.
13. Monrad ES, Hess OM, Murakami T, Nonogi H, Corin WJ, et al. (1988) Time
course of regression of left ventricular hypertrophy after aortic valve
replacement. Circulation 77: 1345–1355.
14. Sciarretta S, Ferrucci A, Ciavarella GM, De Paolis P, Venturelli V, et al. (2007)
Markers of inflammation and fibrosis are related to cardiovascular damage in
hypertensive patients with metabolic syndrome. Am J Hypertension 20:
784–791.
15. Laviades C, Varo N, Dı ´ez J (2000) Transforming growth factor beta in
hypertensives with cardiorenal damage. Hypertension 36: 517–522.
16. Derhaschnig U, Shehata M, Herkner H, Bur A, Woisetschla ¨ger C, et al. (2002)
Increased levels of transforming growth factor-beta1 in essential hypertension.
Am J Hypertens 15: 207–211.
17. Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, et al. (2009) Circulating
transforming growth factor-beta in Marfan syndrome. Circulation 120:
526–532.
18. Grainger DJ, Mosedale DE, Metcalfe JC (2000) TGF-beta in blood: a complex
problem. Cytokine Growth Factor Rev 11: 133–145.
19. Querejeta R, Lo ´pez B, Gonza ´lez A, Sa ´nchez E, Larman M, et al. (2004)
Increased collagen type I synthesis in patients with heart failure of hypertensive
origin: relation to myocardial fibrosis. Circulation 110: 1263–1268.
20. Wasywich CA, Webster MW, Richards AM, Stewart RA (2006) Coronary sinus
and ascending aortic levels of aldosterone, angiotensin II, and B-type natriuretic
peptide in patients with aortic stenosis and in patients with coronary heart
disease. Am J Cardiol 97: 1068–1072.
21. Kuruvilla L, Nair RR, Umashankar PR, Lal AV, Kartha CC (2007) Endocardial
endothelial cells stimulate proliferation and collagen synthesis of cardiac
fibroblasts. Cell Biochem Biophys 47: 65–72.
22. Diehl P, Nagy F, Sossong V, Helbing T, Beyersdorf F, et al. (2008) Increased
levels of circulating microparticles in patients with severe aortic valve stenosis.
Thromb Haemost 99: 711–719.
23. Jian B, Narula N, Li QY, Mohler ER 3rd, Levy RJ (2003) Progression of aortic
valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes
aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 75:
457–465.
24. Devereux RB, Reichek N (1977) Echocardiographic determination of left
ventricular mass in man. Circulation 55: 613–618.
25. De Simone G, Devereux RB, Daniela SR, Meyer RA (1995) Gender differences
in left ventricular growth. Hypertension 26: 979–983.
26. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, et al.
(1991) Segregation of atrial-specific and inducible expression of an atrial
natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy.
Proc Natl Acad Sci U S A 88: 8277–8281.
TGF-b in Aortic Stenosis
PLoS ONE | www.plosone.org 8 December 2009 | Volume 4 | Issue 12 | e8476